Actualités et vidéos - ANATARA LIFESCIENCES LTD

Sydney, Australia (ABN Newswire) - Anatara Lifesciences (ASX:ANR) is pleased to invite shareholders, investors and interested parties to an online Webinar on the Company's Stage 1 Irritable Bowel Syndrome (IBS) clinical trial results, hosted by Chair, Dr. David Brookes. The webinar will be held on Thursday 19th October 2023 at 11:00am AEDT / 10:30am ACDT / 8:00am AWST For the Q&A session, investors are invited to send questions for the webinar prior to 9:00am AEDT Thursday 19th October 2023 to:...

Melbourne, Australia (ABN Newswire) - 2021 has been a significant year for Anatara Lifesciences Limited (ASX:ANR), as we made steps towards progressing our human health products towards clinical trials, successfully completed animal health studies and progressed licensing discussions. There appears to be a wider appreciation of our human health initiatives with a focus on restoration and maintenance of gastrointestinal tract homeostasis to improve overall wellbeing. Operational review Human...

ObvioHealth Partners with Anatara Lifesciences to Launch First-of-its-kind Decentralized Clinical Trial in Australia PR Newswire NEW YORK, Sept. 30, 2021 NEW YORK , Sept. 30, 2021 /PRNewswire/ -- ObvioHealth, a global Virtual Research Organization (VRO), today announces the launch of a first-of-its kind clinical trial in Australia , using a combination of in-home data collection methods that will reduce, and in some cases, eliminate the need for follow-up visits to clinics. The randomized,...

Melbourne, Australia (ABN Newswire) - Anatara Lifesciences (ASX:ANR), a developer of evidence based solutions for gastrointestinal health in humans and animals, invites shareholders to attend a virtual group briefing with Chief Executive Officer, Steven Lydeamore, on Thursday 9 September 2021 at 11:00am AEST. Hosted by Market Eye, Mr Lydeamore will provide an update on the Company's latest developments and market opportunities. Shareholders will have an opportunity to ask questions at the end of...

Melbourne, Australia (ABN Newswire) - Anatara Lifesciences Limited (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in humans and animals, is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr. Steven Lydeamore, will present today to investors. To view the Presentation, please visit: https://abnnewswire.net/lnk/20846ZE6 About Anatara Lifesciences Limited: Anatara Lifesciences Limited (ASX:ANR) is developing and...

Melbourne, Australia (ABN Newswire) - Anatara Lifesciences Limited (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to announce the launch of its IBS-D Clinical Trial recruitment website. Key highlights - Irritable Bowel Syndrome - diarrhoea subtype (IBS-D) trial recruitment website launched with participant screening to commence - Clinical trial of Anatara's unique Gastrointestinal Re-Programming (GaRP) complementary medicine...

Melbourne, Australia (ABN Newswire) - Anatara Lifesciences (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to announce the successful completion of a challenge study in weaner piglets with its recently developed bromelain-based formulation (BONIFF). To address weaner piglet scour, which is estimated to cost the Australian pig industry more than $7 million per year , Anatara and Ridley initiated a weaner piglet enterotoxigenic E....

Melbourne, Australia (ABN Newswire) - Anatara Lifesciences Limited (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 30 June 2021 (Q4 FY21), along with the Company's Appendix 4C cash flow report. Commenting on the quarter, CEO Steve Lydeamore said, "Anatara is pleased to have made solid progress in obtaining the appropriate approval and grants for our human and animal health...

Melbourne, Australia (ABN Newswire) - Anatara Lifesciences (ASX:ANR), a developer of evidence-based solutions for gastrointestinal diseases in humans and animals, is pleased to announce the transition of Dr David Brookes from Non-Executive Director to Chairman. Sue MacLeman will continue on the Board, transitioning from Chair to Non-Executive Director. The Board determined that, having successfully steered the Company following its decision to focus on the development of products and...

Melbourne, Australia (ABN Newswire) - Anatara Lifesciences (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in humans and animals is pleased to provide this update on clinical trial activities. Commenting on progress made towards the human clinical studies, CEO Steve Lydeamore said, "We are pleased to report on the progress made towards two separate human trials for our Gastrointestinal complementary medicines GaRP and 3FDC. Having recently completed the necessary...

Melbourne, Australia (ABN Newswire) - Anatara Lifesciences (ASX:ANR), a developer of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 31 March 2021, along with the Company's Appendix 4C cash flow report. Commenting on the quarter, CEO Steve Lydeamore said, "Anatara is pleased to have successfully progressed two key milestones during the period - a successful trial for Anatara's proprietary...

Melbourne, Australia (ABN Newswire) - Anatara Lifesciences (ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial on the effects of 3FDC dietary supplementation on psychological functioning in an adult population. Highlights: - Study will evaluate safety and efficacy of 3FDC in adult participants with moderate anxiety, stress or depression - Study design is a Randomised, Double-Blinded and Placebo-Controlled trial to...

Melbourne, Australia (ABN Newswire) - Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce the grant of patent number AU2019204496 entitled "Anti-diarrhea formulation which avoids antimicrobial resistance". - Granting of patent number AU2019204496 strengthens Anatara's intellectual property position (IP) in the treatment and prevention of diarrhea caused by pathogenic microbes - The patent provides the pathway for Anatara to further pursue commercialisation opportunities for Detach(R) -...

Melbourne, Australia (ABN Newswire) - Anatara Lifesciences Ltd (ASX:ANR) provides an update on development and commercialisation activities for human health and animal health projects. Anatara is pleased that activities for the March quarter progressed favourably and near to anticipated timelines. There appears to be a wider appreciation of Anatara's human health initiatives with a focus on using the restoration and/or maintenance of gastrointestinal tract harmony to improve overall wellbeing...

Melbourne, Australia (ABN Newswire) - On 14 December 2020, Anatara Lifesciences Limited (ASX:ANR) announced details of an off-market share buy-back facility (Buy-Back Facility) to buyback all of the shares held by shareholders who held unmarketable parcels of shares in the Company (Eligible Shareholders) as at 7:00 p.m. (Melbourne time) on Friday, 11 December 2020 (Record Date). In accordance with the terms of the Buy-Back Facility, Eligible Shareholders had until 7:00pm (Melbourne time) Friday,...

Melbourne, Australia (ABN Newswire) - Anatara Lifesciences (ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial of its Gastrointestinal Re-Programming complementary medicine (GaRP) in participants with irritable bowel syndrome - diarrhoea subtype (IBS-D). Highlights: - Study will evaluate safety and efficacy of GaRP in patients with IBS (irritable bowel syndrome) - Study design is Randomised, Double-Blinded and...

Melbourne, Australia (ABN Newswire) - Anatara Lifesciences (ASX:ANR) is pleased to announce successful completion of the poultry challenge trial "Efficacy of ANR-pf on the performance of broilers subject to subclinical and necrotic enteritis challenges". ANR-pf is Anatara's proprietary enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method on-farm even when stock illness is a concern. The study was a randomised,...

Melbourne, Australia (ABN Newswire) - Anatara Lifesciences (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2020. The Company's cash plus term deposits at the end of the quarter stood at $3.68m (30th September 2020: $1.59m). On 31st December 2020, the Company had cash at bank of $1.68m and $2.0m in term deposits. Net cash outflow during the quarter was 28% lower than the prior quarter primarily due to timing of expenditure on the GaRP clinical trial. Aggregate...

Melbourne, Australia (ABN Newswire) - Anatara Lifesciences (ASX:ANR) is pleased to advise that it is planning initiation of a human clinical study on changes to psychological functioning in adults with a moderate level of depression, anxiety or stress symptoms, in response to use of the Company's recently developed colon-targeted formulation (3FDC). Anatara has been awarded an Innovation Connections Grant, under the Australian Government's Entrepreneurs' Programme, with funding to be provided to...

Melbourne, Australia (ABN Newswire) - The last twelve months have seen exciting developments as Anatara Lifesciences Ltd (ASX:ANR) advances our lead human health product, our Gastrointestinal ReProgramming (GaRP) complementary medicine. The market opportunity for gastrointestinal supplements and OTC digestive remedies in USA alone is US$8 billion. Leading products include Bayer's Iberogast with sales in Germany of US$145 million. GaRP is a regenerative, multi-component complementary medicine...